Efficacy of Antituberculous Therapy in Management of Sarcoidosis
Sarcoidosis, Tuberculosis
About this trial
This is an interventional treatment trial for Sarcoidosis focused on measuring Sarcoidosis, Tuberculosis
Eligibility Criteria
Inclusion Criteria:
newly diagnosed sarcoidosis defined by presence of all of the following criteria:
- Presence with clinical features of pulmonary (dyspnea, dry cough, chest pain, fever, fatigue or crackles) or extra pulmonary organ (lymph nodes, liver, spleen, skin, eyes, heart, etc.) involvement and consistent radiological involvement and
- Compact non-caseating granulomas on trans-bronchial biopsy which are tissue AFB smear-negative
Exclusion Criteria:
Patients who have received glucocorticoid treatment before initial evaluation by us, or with presence of concomitant other cardio pulmonary disease will be excluded.
Sites / Locations
- Deaprtment of Pulmonary Medicine, PGIMER
Arms of the Study
Arm 1
Active Comparator
Glucocorticoid arm
Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 6 weeks (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 6 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year